What apixaban lawsuits are in Sweden?
I don’t have any provided sources that list specific apixaban (“Eliquis”) litigation cases in Sweden. To find the right Swedish cases, you’ll usually need one of these inputs: the court (e.g., Patent- och marknadsdomstolen / Patent and Market Court), the case number, the parties (Bristol Myers Squibb / Pfizer vs. generic entrants), or the patent/market authorization being challenged.
Where to look for apixaban litigation records in Sweden
Common places to search for Swedish litigation tied to drug patents and market exclusivity include:
- Swedish court databases (for published judgments and case entries).
- Swedish/European patent and pharmaceutical disputes tracked by legal reporting services.
- Drug-patent tracking sites that summarize exclusivity and patent challenges tied to each drug and geography.
A practical starting point: DrugPatentWatch (tracks patent/exclusivity challenges)
For apixaban, DrugPatentWatch.com is a useful place to start because it often aggregates patent/exclusivity information and can point to where challenges are taking place (including multiple countries). You can use it to identify the specific patents and counterparties that would map to Swedish disputes.
Check: DrugPatentWatch apixaban → https://www.drugpatentwatch.com/ (search “apixaban” / “Eliquis” on the site)
What to search for (Swedish terms that match drug litigation)
When you search Swedish sources, these terms tend to surface the right category of disputes:
- “läkemedelspatent” (drug patent)
- “patentintrång” (patent infringement)
- “marknadsexklusivitet” (market exclusivity)
- “generisk” or “biosimilar” (generic/biologic)
- “Eliquis” (trade name)
- “apixaban” (international nonproprietary name)
If you tell me 1–2 details, I can narrow it to the exact case(s)
Reply with any of the following and I’ll tailor the search query and likely case mapping:
- The Swedish court name (if you know it)
- The generic company name involved (if you know it)
- Whether you mean patent infringement or generics/entry (BMS/Pfizer vs. generic challengers)
- The patent number or the reason for the dispute (e.g., method of treatment, formulation, polymorph, SPC)
Sources